Loading…
Lyell Immunopharma, Inc. is projected to rise to $18.29 by 2027, a +9% move from its current price of $16.73. LYEL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $16.16 | $16.72 | $17.30 | -0.03% |
| May 30 | $15.93 | $16.72 | $17.54 | -0.06% |
| May 31 | $15.76 | $16.71 | $17.73 | -0.09% |
| Jun 1 | $15.61 | $16.71 | $17.89 | -0.12% |
| Jun 2 | $15.48 | $16.70 | $18.03 | -0.15% |
| Jun 3 | $15.36 | $16.70 | $18.15 | -0.19% |
| Jun 4 | $15.25 | $16.69 | $18.27 | -0.22% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.25 | $16.69 | $18.27 | -0.22% |
| Week 2 | $14.66 | $16.66 | $18.92 | -0.43% |
| Week 3 | $14.22 | $16.62 | $19.43 | -0.65% |
| Week 4 | $13.85 | $16.59 | $19.86 | -0.86% |
| Week 5 | $13.53 | $16.55 | $20.24 | -1.08% |
| Week 6 | $13.24 | $16.51 | $20.59 | -1.29% |
| Week 7 | $12.98 | $16.48 | $20.92 | -1.51% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity.
Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Lyell Immunopharma, Inc. ( LYEL ) operates in the Healthcare sector. The current price is $17.46 and the market cap is $407.41M, with a market rank of 3211. These figures place the stock within a broad, early-stage biotechnology landscape.
The stock’s near-term price trajectory is reflected in the 30-day technical picture and the ongoing forecast, which anchors pricing expectations through the next several years. In the near term, the 30-day view and range provide context for entry and risk management.
A major floor 37.3% below — a decisive break under it would weaken the trend.
The nearest floor, 3.6% below — buyers have tended to step in here.
The nearest ceiling, 48.8% above — a clean break opens room to run.
A major ceiling 67.4% above — clearing it would confirm fresh momentum.
Key LYEL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LYEL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.02 | Sell | $16.94 | Sell |
| MA 10 | $17.39 | Sell | $17.50 | Sell |
| MA 20 | $18.75 | Sell | $18.62 | Sell |
| MA 50 | $20.64 | Sell | $20.42 | Sell |
| MA 100 | $22.39 | Sell | $21.25 | Sell |
| MA 200 | $20.53 | Sell | $20.58 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.54 | Neutral |
| Stoch RSI (14) | 59.67 | Neutral |
| CCI (20) | -93.75 | Neutral |
| Williams %R (14) | -84.73 | Info |
| MACD (12,26,9) | -0.16 | Sell |
| ROC (12) | -13.45 | Sell |
| Bollinger %B (20,2) | 0.19 | Neutral |
| Stochastic %K (14) | 15.27 | Buy |
| TRIX (15) | -0.84 | Sell |
| Awesome (5,34) | -3.71 | Sell |
| Ultimate (7,14,28) | 32.00 | Neutral |
| Momentum (10) | -2.52 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 16.81 | Sell |
| ADX (14) | 25.64 | Sell |
| ATR (14) | 0.61 | Info |
The 30-day technical picture is NEUTRAL. RSI14 stands at 40, and the near-term trend is quiet with no clear momentum. The SMA50 sits at $20.82 and the SMA200 at $20.48, offering nearby support and resistance reference levels. A key support level is $16.13, with resistance around $24.89. The 30-day price range spans from a low of $14.01 to a high of $21.77.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.13 | $16.73 | $24.39 | 0% | Neutral | |
| $14.16 | $18.29 | $25.23 | +9% | Neutral | |
| $13.49 | $18.04 | $25.98 | +8% | Neutral | |
| $13.24 | $18.24 | $27.17 | +9% | Neutral | |
| $12.68 | $17.93 | $27.47 | +7% | Neutral | |
| $14.18 | $20.54 | $32.27 | +23% | Bullish | |
| $16.05 | $23.78 | $38.19 | +42% | Bullish | |
| $16.90 | $25.59 | $41.93 | +53% | Bullish | |
| $17.29 | $26.72 | $44.59 | +60% | Bullish | |
| $16.48 | $25.96 | $44.08 | +55% | Bullish | |
| $20.82 | $35.91 | $65.47 | +115% | Bullish | |
| $30.05 | $60.92 | $123.12 | +264% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $16.13 | $16.73 | $19.76 | +0.00% |
| June 2026 | $14.06 | $16.60 | $20.13 | -0.78% |
| July 2026 | $13.63 | $16.26 | $20.05 | -2.02% |
| August 2026 | $14.05 | $16.90 | $21.11 | +3.91% |
| September 2026 | $14.45 | $17.50 | $22.09 | +3.58% |
| October 2026 | $14.30 | $17.43 | $22.20 | -0.42% |
| November 2026 | $14.55 | $17.83 | $22.90 | +2.30% |
| December 2026 | $15.29 | $18.85 | $24.39 | +5.70% |
Click any year to see its month-by-month LYEL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, LYEL could reach as high as $24.39, with a base case around $16.73 and support toward $16.13 — roughly 0% from $16.73. A consolidation phase looks the most probable path here.
Expect LYEL to range from $14.16 to $25.23 through 2027. The $18.29 average target implies a +9% move from current prices. That is up +9% on the projected 2026 average. Price action looks broadly range-bound.
The LYEL price prediction for 2028 points to an average of $18.04 (low $13.49, high $25.98) — a potential gain of +8% on today's $16.73. A consolidation phase looks the most probable path here.
In 2029, LYEL is projected to trade between $13.24 and $27.17, averaging $18.24 — a potential gain of +9% from today's $16.73. That is up +1% on the projected 2028 average. Price action looks broadly range-bound.
Lyell Immunopharma, Inc.'s 2030 outlook centres on $17.93, within a $12.68 to $27.47 range. That is -2% versus the projected 2029 average. That marks a +7% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, LYEL could reach as high as $32.27, with a base case around $20.54 and support toward $14.18 — roughly +23% from $16.73. Momentum favours further upside here.
Expect LYEL to range from $16.05 to $38.19 through 2032. The $23.78 average target implies a +42% move from current prices. That is up +16% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The LYEL price prediction for 2033 points to an average of $25.59 (low $16.90, high $41.93) — a potential gain of +53% on today's $16.73. Momentum favours further upside here.
In 2034, LYEL is projected to trade between $17.29 and $44.59, averaging $26.72 — a potential gain of +60% from today's $16.73. That is up +4% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Lyell Immunopharma, Inc.'s 2035 outlook centres on $25.96, within a $16.48 to $44.08 range. That is -3% versus the projected 2034 average. That marks a +55% change versus current levels. Momentum favours further upside here.
By 2040, LYEL could reach as high as $65.47, with a base case around $35.91 and support toward $20.82 — roughly +115% from $16.73. Buyers look set to stay in control over this stretch.
Expect LYEL to range from $30.05 to $123.12 through 2050. The $60.92 average target implies a +264% move from current prices. That is up +70% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in LYEL today (≈ 59.772863 LYEL) could be worth
$3,641.24
+$2,641.24 (+264%) by 2050 · US Dollar
Based on the average projected LYEL price of $60.92 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LYELwould be worth at today's price.
$1,000 invested in LYEL on May 27, 2025 (≈ 121.654497 LYEL) would be worth
$2,035.28
+$1,035.28 (+103.5%) today · 2.04× · US Dollar
Based on a LYEL entry price of $8.22 vs. today's $16.73.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.22 | $971.54 | -2.8% |
| 1 month ago | $22.62 | $739.61 | -26.0% |
| 3 months ago | $23.01 | $727.08 | -27.3% |
| 6 months ago | $24 | $697.08 | -30.3% |
| 1 year ago | $8.22 | $2,035.28 | +103.5% |
| All time (4.9y) ago | $337.8 | $49.53 | -95.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LYEL forecast.
Our base-case forecast reaches $33.00 around 2040.
Implied market cap at $33.00: $770.02M
The multi-year forecast sketches a path from a flat near-term start to meaningful upside in the longer horizon. For 2030 the average forecast is $18.79 with a minimum of $13.34 and a maximum of $28.67, and a reported ROI of 7.6. By 2031 the sentiment turns BULLISH with an average of $21.80 and a maximum of $34.09, delivering a 24.9 ROI.
The trajectory remains bullish through 2034 (avg $28.35, max $47.05, ROI 62.4) and 2035 (avg $27.48, max $46.40, ROI 57.4). By 2040 the average is $38.25 and the max is $69.29, with a projected ROI of 119.1 and a BULLISH sentiment. The 2050 forecast shows an average of $65.36 and a max of $131.06, with a strong projected ROI of 274.3 and a BULLISH sentiment.
These figures illustrate potential upside over the long run, though they are estimates and carry inherent uncertainty and risk.
Tap a question to reveal the answer.
2030 avg $18.79, min $13.34, max $28.67, ROI 7.6.
Forecasts show positive long-term upside, with bullish sentiment from 2031 onward and averages such as $21.80 in 2031, $38.25 by 2040, and $65.36 by 2050, with max values up to $34.09 (2031), $69.29 (2040), and $131.06 (2050). ROI in these years ranges up to 24.9, 119.1, and 274.3 respectively.
Yes. The forecast maximum by 2050 is $131.06, which would exceed $100.
2028 avg $18.90, min $14.17, max $27.13, ROI 8.3.
Yes. The 2031 forecast sentiment is BULLISH with avg $21.80, min $15.12, max $34.09, ROI 24.9.
Lyell Immunopharma, Inc. Community Discussion
0Share your Lyell Immunopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.